4/A: Nuo Therapeutics Executive Buys Shares
Insider Transaction (Form 4/A)
David Emerson Jorden, CEO/CFO and a Director of Nuo Therapeutics, Inc., purchased 8,773 shares of common stock on August 27, 2026.
Summary
- Open-market purchase: acquired 789 Common Stock at $1.07 ($844) on August 27, 2026; holds 2,062,016 after (Direct).
- Open-market purchase: acquired 7,984 Common Stock at $1.09 ($8,695) on August 28, 2026; holds 2,070,000 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $9,539, committing personal capital to the stock.
Insider Transactions
David Emerson Jorden — Director, Officer (CEO/CFO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-27 | Open-market purchase | Common Stock | 789 | $1 | $844 | 2,062,016 |
| 2026-08-28 | Open-market purchase | Common Stock | 7,984 | $1 | $8.7K | 2,070,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-27 | Open-market purchase (789 shares) |
| 2026-08-28 | Open-market purchase (7,984 shares) |
Keywords
insider transaction, Form 4/A, AURX, Nuo Therapeutics, Inc., bullish, David Emerson Jorden
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.